131I-Rituximab Treatment in Patient with
Relapsed Non-Hodgkin’s Lymphoma:
The First Case Report in Thailand
Arpakorn Kositwattanarerk MD*,
Wirote Changmuang MSc*, Jatupol Sangsuriyan MSc**, Kittiphong Thongklam BSc*,
Chanika Sritara MD*, Chirawat Utamakul MD*, Wichana Chamroonrat MD*,
Kanungnij Thamnirat MD*, Yoch Anongpornyochkul MD*, Suporn Chancharunee MD***
Affiliation :
* Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand
** Radioisotope Center, Thailand Institute of Nuclear Technology (Public Organization), Bangkok, Thailand
*** Department of Medicine, Faculty of Medicine, Ramathibodi Hostital, Mahidol University, Bangkok, Thailand
Radioimmunotherapy (RIT) with 131I-rituximab is a safe and effective treatment in patients with relapsed, refractory
follicular lymphoma. The authors demonstrated the first case of 131I-rituximab treatment in the patient with relapsed
non-Hodgkin’s lymphoma (NHL) in Thailand. There was no immediate complication after treatment. Impressive treatment
response occurred.
Keywords : 131I-rituximab, Non-Hodgkin’s lymphoma, Radioimmunotherapy
All Articles
Download